Aspen Pharmacare Holdings Limited (JSE:APN)
South Africa · Delayed Price · Currency is ZAR · Price in ZAc 9,814.00
+302.00 (3.17%)
Oct 31, 2025, 5:00 PM SAST
Aspen Pharmacare Holdings Income Statement
Financials in millions ZAR. Fiscal year is July - June.
Millions ZAR. Fiscal year is Jul - Jun.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | 2016 - 2020 |
| 43,363 | 44,706 | 40,709 | 38,606 | 37,766 | Upgrade | |
Revenue Growth (YoY) | -3.00% | 9.82% | 5.45% | 2.22% | 12.20% | Upgrade |
Cost of Revenue | 24,311 | 25,290 | 21,840 | 20,350 | 19,987 | Upgrade |
Gross Profit | 19,052 | 19,416 | 18,869 | 18,256 | 17,779 | Upgrade |
Selling, General & Admin | 10,949 | 10,100 | 9,394 | 8,522 | 9,109 | Upgrade |
Other Operating Expenses | 1,109 | 449 | 546 | 991 | 558 | Upgrade |
Operating Expenses | 12,058 | 10,549 | 9,940 | 9,516 | 9,672 | Upgrade |
Operating Income | 6,994 | 8,867 | 8,929 | 8,740 | 8,107 | Upgrade |
Interest Expense | -1,715 | -2,279 | -1,362 | -829 | -1,252 | Upgrade |
Interest & Investment Income | 358 | 1,059 | 529 | 105 | 140 | Upgrade |
Currency Exchange Gain (Loss) | 110 | -49 | -688 | 46 | -147 | Upgrade |
Other Non Operating Income (Expenses) | -313 | -15 | 254 | 138 | 98 | Upgrade |
EBT Excluding Unusual Items | 5,434 | 7,583 | 7,662 | 8,200 | 6,946 | Upgrade |
Merger & Restructuring Charges | -848 | -227 | -278 | -171 | -318 | Upgrade |
Impairment of Goodwill | - | -145 | - | -11 | -131 | Upgrade |
Gain (Loss) on Sale of Assets | - | - | - | 1,212 | 165 | Upgrade |
Asset Writedown | -4,743 | -1,522 | -1,064 | -1,194 | -632 | Upgrade |
Legal Settlements | - | - | - | -75 | -41 | Upgrade |
Pretax Income | -123 | 5,714 | 6,555 | 8,134 | 5,989 | Upgrade |
Income Tax Expense | 960 | 1,310 | 1,327 | 1,646 | 1,191 | Upgrade |
Earnings From Continuing Operations | -1,083 | 4,404 | 5,228 | 6,488 | 4,798 | Upgrade |
Earnings From Discontinued Operations | - | - | - | - | 8 | Upgrade |
Net Income to Company | -1,083 | 4,404 | 5,228 | 6,488 | 4,806 | Upgrade |
Net Income | -1,083 | 4,404 | 5,228 | 6,488 | 4,806 | Upgrade |
Net Income to Common | -1,083 | 4,404 | 5,228 | 6,488 | 4,806 | Upgrade |
Net Income Growth | - | -15.76% | -19.42% | 35.00% | 3.04% | Upgrade |
Shares Outstanding (Basic) | 444 | 444 | 444 | 453 | 457 | Upgrade |
Shares Outstanding (Diluted) | 444 | 444 | 444 | 453 | 457 | Upgrade |
Shares Change (YoY) | -0.04% | - | -1.94% | -0.77% | - | Upgrade |
EPS (Basic) | -2.44 | 9.91 | 11.77 | 14.32 | 10.53 | Upgrade |
EPS (Diluted) | -2.44 | 9.91 | 11.77 | 14.32 | 10.53 | Upgrade |
EPS Growth | - | -15.76% | -17.83% | 36.04% | 3.04% | Upgrade |
Free Cash Flow | 2,583 | 3,108 | 3,290 | 3,411 | 4,780 | Upgrade |
Free Cash Flow Per Share | 5.82 | 7.00 | 7.41 | 7.53 | 10.47 | Upgrade |
Dividend Per Share | 2.110 | 3.590 | 3.420 | 3.260 | 2.620 | Upgrade |
Dividend Growth | -41.23% | 4.97% | 4.91% | 24.43% | - | Upgrade |
Gross Margin | 43.94% | 43.43% | 46.35% | 47.29% | 47.08% | Upgrade |
Operating Margin | 16.13% | 19.83% | 21.93% | 22.64% | 21.47% | Upgrade |
Profit Margin | -2.50% | 9.85% | 12.84% | 16.81% | 12.73% | Upgrade |
Free Cash Flow Margin | 5.96% | 6.95% | 8.08% | 8.83% | 12.66% | Upgrade |
EBITDA | 8,513 | 10,276 | 10,189 | 9,933 | 9,183 | Upgrade |
EBITDA Margin | 19.63% | 22.99% | 25.03% | 25.73% | 24.32% | Upgrade |
D&A For EBITDA | 1,519 | 1,409 | 1,260 | 1,193 | 1,076 | Upgrade |
EBIT | 6,994 | 8,867 | 8,929 | 8,740 | 8,107 | Upgrade |
EBIT Margin | 16.13% | 19.83% | 21.93% | 22.64% | 21.47% | Upgrade |
Effective Tax Rate | - | 22.93% | 20.24% | 20.24% | 19.89% | Upgrade |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.